Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
26.88 ^USD	+3.86%		+16.46%	-1.25%

Jul. 09	RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk	MT
Jul. 01	Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 3000 Growth Index	CI

Beam Therapeutics Inc. Reports Earnings Results for the Nine Months Ended September 30, 2019

January 17, 2020 at 04:11 pm EST

Beam Therapeutics Inc. announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced operating loss was USD 48.783 million compared to USD 32.178 million a year ago. Net loss was USD 50.476 million compared to USD 90.063 million a year ago. Basic loss per share was USD 2.14 compared to USD 9.9 a year ago.

Latest news about Beam Therapeutics Inc.

RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk	Jul. 09	MT
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 3000 Growth Index	Jun. 30	CI
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 3000E Growth Index	Jun. 30	CI
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 2000 Growth Index	Jun. 30	CI
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 2500 Growth Index	Jun. 30	CI
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell Small Cap Comp Growth Index	Jun. 30	CI
Beam Therapeutics Insider Sold Shares Worth $1,470,156, According to a Recent SEC Filing	Jun. 28	MT
Beam Therapeutics Inc. Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency	Jun. 26	CI
Beam Therapeutics Inc. Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease	Jun. 14	CI
Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates	May. 07	MT
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	Mar. 26	MT
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	Mar. 26	CI
Transcript : Beam Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:35 PM	Mar. 13
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	Feb. 28	MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	Feb. 28	MT
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup	Feb. 27	DJ
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	Feb. 27	MT
Beam Therapeutics Shares Jump on Surprise Q4 Profit	Feb. 27	MT
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	Feb. 27	MT
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto	Jan. 30	MT
North American Morning Briefing : Microsoft Kicks -2-	Jan. 30	DJ

Chart Beam Therapeutics Inc.

Duration

Period

More charts

Company Profile

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 30, 2024 at 02:21 pm EST

More Strategies

Ratings for Beam Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.88 USD

Average target price

47.77 USD

Spread / Average Target

+84.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BEAM THERAPEUTICS INC.	-1.25%	2.04B
MODERNA, INC.	+22.10%	47.07B
LONZA GROUP AG	+46.45%	42.06B
IQVIA HOLDINGS INC.	-3.12%	39.98B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	33.02B
CELLTRION, INC.	-6.30%	27.9B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.63B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.37B
MEDPACE HOLDINGS, INC.	+44.52%	13.45B
BIO-TECHNE CORPORATION	+0.19%	12.03B

Other Biotechnology & Medical Research